GlassScriptPhysician profile
Oksana Berkovich
NPI 1245291269
$2,410.22
in general payments reported to CMS, 2019-2025
24 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.12 · 2020: $144 · 2021: $305 · 2022: $312 · 2023: $394 · 2024: $492 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $576.59 | 2019-2025 | Ztlido |
| Abbvie INC. | $352.33 | 2019-2025 | Ubrelvy, Vraylar |
| Teva Pharmaceuticals USA, INC. | $171.35 | 2022-2024 | Austedo Xr, Austedo |
| Pfizer INC. | $164.33 | 2020-2025 | |
| Lilly USA, LLC | $137.44 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $136.74 | 2025 | Veozah |
| Acadia Pharmaceuticals INC | $122.07 | 2024 | Nuplazid |
| Amgen INC. | $119.26 | 2020-2024 | Krystexxa, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.61 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $107.71 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $81.29 | 2023-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $61.74 | 2021-2023 | Verquvo |
| Glaxosmithkline, LLC. | $47.28 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $34.70 | 2024 | Cologuard Collection Kit |
| Emd Serono, INC. | $26.79 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.87 | 2025 | Vyepti |
| Novo Nordisk INC | $22.85 | 2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $20.01 | 2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $19.52 | 2023 | Horizant |
| Aimmune Therapeutics, INC. | $18.19 | 2024 | |
| Amarin Pharma, INC. | $16.03 | 2020 | |
| Embecta Corp. | $15.24 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Phadia US INC. | $14.55 | 2023 | Immunocap |
| Novartis Pharmaceuticals Corporation | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oksana Berkovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.